Total revenue is expected to increase by a low-to-mid single-digit percentage. Excluding COVID-19 medicines, total revenue is expected to increase by a low double-digit percentage. Core EPS is expected to increase by a high single-digit to low double-digit percentage. Total revenue from COVID-19 medicines — Vaxzevria14 and COVID-19 mAbs15 — is expected to decline significantly in FY23, with minimal revenue from Vaxzevria.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN: